The coronavirus pandemic has shaken the global economy, but three life sciences venture capital firms this week announced new funds totaling nearly $3 billion.
ARCH Venture Partners led the pack, adding two funds totaling $1.46 billion to its war chest. Flagship... Read more »
Investors worried about a recession like venBio Partners’ risk-mitigated approach to venture capital investing. That approach has led new limited partners to join earlier backers in putting nearly $400 million into the San Francisco-based firm’s new fund.
VenBio announced Friday it... Read more »
Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.
One proved eerily prescient: The... Read more »
Immunotherapies called checkpoint inhibitors have helped change the way a number of cancers are treated by blocking a tumor cell’s ability to hide from the immune system.
Some patients don’t respond, however, or develop resistance to these drugs. Iteos Therapeutics has... Read more »
Pandion Therapeutics emerged in 2018 aiming to reach clinic trials in two years testing its biologic drugs in autoimmune and inflammatory disorders. The company now has $80 million to support a lead program in early-stage testing and a pipeline of potential... Read more »
Cameron Hewitt’s family celebrates the anniversary of her life not once, but twice yearly: Besides her September birthday, they commemorate a day in March—the anniversary of two-year-old Cameron receiving the gene therapy that gave her a new shot at life.
Cameron... Read more »
Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that treat a disease or spark immunity to one.
Sanofi (NYSE: SNY... Read more »
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible.
Fallout from the spread of COVID-19 infections led several companies to declare this week that they would stop enrolling patients in clinical trials... Read more »
Future improvements in cancer care are most likely to stem from combinations therapies and data-driven prevention efforts, as well as breakthrough drugs.
That’s the message life sciences experts shared this week during a webcast on the topic of “oncology’s next decade”... Read more »
Regenacy Pharmaceuticals, a biotech formed as part of Celgene’s acquisition of Acetylon Pharmaceuticals in late 2016, has raised $30 million in Series A financing to move its lead program into a Phase 2 proof-of-concept trial this year.
The Waltham, MA-based... Read more »
After years of research, technology for silencing a gene—stopping it from producing a disease-causing protein—has reached patients. AstraZeneca is now angling for a position in this burgeoning field through an alliance with Silence Therapeutics, a biotech developing such gene-silencing drugs.
According... Read more »
The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans.
“I think that fear of losing out has pretty much gone out the window right now,” said Equillium (NASDAQ: EQ) CEO... Read more »
Keros Therapeutics, a biotech which raised more than $50 million this month in venture capital, is now looking to tap the public markets for additional cash amid a time of historic tumult.
The Lexington, MA-based company, is a clinical-stage biotech that... Read more »
The past week brought a sea change in many of our daily lives as the impact of the continued spread of the novel coronavirus altered how we work and play as communities around the world attempt to slow its spread.
Xconomy,... Read more »
The following sponsored content was submitted by commercial real estate brokerage firm Hughes Marino:
The story of the “canary in the coal mine” is an advanced warning of danger. The metaphor originates from when miners used to carry caged canaries... Read more »
The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but not in any way that people wanted or expected.
The World Health Organization this week... Read more »
Rubius Therapeutics is dropping its lead drug candidate—and its focus on rare diseases—in favor of earlier-stage cell therapies that it has been developing for oncology and autoimmune disorders.
The Cambridge, MA-based company disclosed the strategy shift Thursday in its report of... Read more »
A biotech born out of an antibody platform company has added another $75 million to its investment haul, money it says will allow it to advance its clinical-stage compounds and continue to build its portfolio of earlier-stage therapeutics.
Shanghai-based Harbour BioMed... Read more »
The global economy is in tumult as the new coronavirus sparks financial contagion but drug developer Imara pressed ahead with its IPO anyway, raising $75.2 million in its stock market debut.
Late Wednesday, Imara offered 4.7 million shares for $16 apiece,... Read more »
Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised... Read more »
An experimental Acceleron Pharma drug for rare neuromuscular diseases has failed to distance itself from a placebo in a mid-stage study, spelling the end for that program.
Acceleron (NASDAQ: XLRN) drug ACE-083 was being developed as a treatment for Charcot-Marie-Tooth... Read more »
A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data.
Last August the FDA rejected a Kala (NASDAQ: KALA) product meant to temporarily relieve signs... Read more »
Sponsored · Whitepaper
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson
Sponsored · Whitepaper
Create well-controlled, biologically relevant test systems and validate them to support FDA approvals
Absorption Systems
Sponsored · Whitepaper
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson
